A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Clinical trial NCT05424835 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05424835
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-04
- Primary completion
- 2026-12-31
- Enrollment
- 381
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.